Gene signatures distinguish stage-specific prostate cancer stem cells isolated from transgenic adenocarcinoma of the mouse prostate lesions andpredict the malignancy of human tumors

Stem Cells Translational Medicine

Volumn 2, Issue 9, 2013, Pages 678-689

  Mazzoleni, Stefania ^a,b   Jachetti, Elena ^b,c   Morosini, Sara ^a,b   Grioni, Matteo ^b,c   Piras, Ignazio Stefano ^d   Pala, Mauro ^e   Bulfone, Alessandro ^e   Freschi, Massimo ^f   Bellone, Matteo ^b,c   Galli, Rossella ^a,b  

^a San Raffaele Scientific InstituteMilano   (Italy)

^b Infectious Diseases and Transplantation   (Italy)

^c Clinic of Infectious Diseases   (Italy)

^d CENTER FOR ADVANCED STUDIES   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f BioFlag Ltd   (Italy)

Author keywords

Cancer; Cancer stem cells; Gene expression; Neoplastic stem cell biology

Indexed keywords

ANDROGEN RECEPTOR; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 8; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL ISOLATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

MUS;

EID: 84883370295     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2013-0041     Document Type: Article

References (51)

1. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
2. Jadvar H. Prostate cancer. Methods Mol Biol 2011;727:265-290.
3. Roy-Burman P, Wu H, Powell WC et al. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004;11:225-254.
4. Dickinson SI. Premalignant and malignant prostate lesions: Pathologic review. Cancer Control 2010;17:214-222.
5. Kaplan-Lefko PJ, Chen TM, Ittmann MM et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237.
6. Hurwitz AA, Foster BA, Allison JP et al. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol 2001. Chapter 20:Unit 20.5.
7. Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
8. Gingrich JR, Barrios RJ, Morton RA et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
9. Foster BA, Gingrich JR, Kwon ED et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-3330.
10. Chiaverotti T, Couto SS, Donjacour A et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-246.
11. Abate-Shen C. A new generation of mouse models of cancer for translational research. Clin Cancer Res 2006;12:5274-5276.
12. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497-511.
13. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 2010;24:1967-2000.
14. Han G, Foster BA, Mistry S et al. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem 2001;276:11204-11213.
15. Schatten H, Wiedemeier AM, Taylor M et al. Centrosome-centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell 2000;92:331-340.
16. Shappell SB, Thomas GV, Roberts RL et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-2305.
17. Nguewa PA, Calvo A. Use of transgenic mice as models for prostate cancer chemoprevention. Curr Mol Med 2010;10:705-718.
18. Huang Z, Hurley PJ, Simons BW et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012;3: 651-663.
19. Yoshioka T, Otero J, Chen Y et al._4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest 2013;123:682-699.
20. Chiam K, Ryan NK, Ricciardelli C et al. Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate 2013;73:182-193.
21. Carvalho FL, Simons BW, Antonarakis ES et al. Tumorigenic potential of circulating prostate tumor cells. Oncotarget 2013;4:413-421.
22. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines: Part 2. J Urol 2005;173:360-372.
23. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines: Part 1. J Urol 2005;173:342-359.
24. Baley PA, Yoshida K, Qian W et al. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem Mol Biol 1995;52:403-413.
25. Tsujimura A, Koikawa Y, Salm S et al. Proximal location of mouse prostate epithelial stem cells: A model of prostatic homeostasis. J Cell Biol 2002;157:1257-1265.
26. Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011;30:1261-1271.
27. Burger PE, Xiong X, Coetzee S et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 2005;102:7180-7185.
28. Lawson DA, Xin L, Lukacs RU et al. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 2007;104:181-186.
29. Goldstein AS, Lawson DA, Cheng D et al. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008;105: 20882-20887.
30. Goldstein AS, Huang J, Guo C et al. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-571.
31. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951.
32. Mulholland DJ, Xin L, Morim A et al. Lin- Sca-1CD49fhigh stem/progenitors are tumor- initiating cells in the Pten-null prostate cancer model. Cancer Res 2009;69:8555-8562.
33. Liao CP, Adisetiyo H, Liang M et al. Cancer- associated fibroblasts enhance the glandforming capability of prostate cancer stem cells. Cancer Res 2010;70:7294-7303.
34. Xin L, Lukacs RU, Lawson DA et al. Selfrenewal and multilineage differentiation in vitro from murine prostate stem cells. STEM CELLS 2007;25:2760-2769.
35. Lukacs RU, Goldstein AS, Lawson DA et al. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc 2010;5:702-713.
36. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
37. Galli R, Binda E, Orfanelli U. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7021.
38. Bertilaccio MT, Grioni M, Sutherland BW et al. Vasculature-targeted tumor necrosis factor- alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 2008;68:1105-1115.
39. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: A knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550.
40. Wang Y, Xia XQ, Jia Z et al. In silico estimates of tissue components in surgical samples based on expression profiling data. Cancer Res 2010;70:6448-6455.
41. Varambally S, Yu J, Laxman B et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
42. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255:1707-1710.
43. Blum R, Gupta R, Burger PE et al. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One 2009;4:e5722.
44. Kela I, Harmelin A, Waks T et al. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate 2009;69:1034-1044.
45. Hu Y, Ippolito JE, Garabedian EM et al. Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. J Biol Chem 2002;277: 44462-44474.
46. Beltran H, Rickman DS, Park K et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-495.
47. Gu G, Yuan J, Wills M. et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67: 4807-4815.
48. Reynolds BA, Rietze RL. Neural stem cells and neurospheres: Re-evaluating the relationship. Nat Methods 2005;2:333-336.
49. Huss WJ, Gray DR, Tavakoli K et al. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 2007;9: 938-950.
50. Ju X, Ertel A, Casimiro MC et al. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res 2013;73:978-989.
51. Komiya A, Suzuki H, Imamoto T et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009;16:37-44.